GlassScriptPhysician profile
Robert L Rosentreter
NPI 1780340851
$2,336.54
in general payments reported to CMS, 2019-2025
21 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,208 · 2023: $761 · 2024: $147 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $683.38 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $395.16 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $217.80 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $212.23 | 2022 | |
| Glaxosmithkline, LLC. | $171.41 | 2022-2025 | Shingrix, Arexvy, Penmenvy |
| Lilly USA, LLC | $89.39 | 2022-2024 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $84.70 | 2022 | |
| Exact Sciences Corporation | $75.47 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $70.87 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.66 | 2022 | |
| Neurocrine Biosciences, INC. | $46.43 | 2022-2023 | Ongentys, Ingrezza |
| Janssen Pharmaceuticals, INC | $43.03 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $39.28 | 2022-2023 | Austedo Xr |
| Astellas Pharma US INC | $23.36 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.14 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $21.12 | 2022 | |
| Antares Pharma, INC. | $21.03 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.57 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.23 | 2023 | |
| Sanofi-Aventis U.S. LLC | $13.67 | 2022 | |
| Alexion Pharmaceuticals, INC. | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rosentreter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.